merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Significant safety risks including brain swelling and bleeding alongside only modest slowing of decline.</answer>
<question_number>2</question_number>
<answer>It may discourage patients from participating in trials for potentially better treatments.</answer>
<question_number>3</question_number>
<answer>No correlation between plaque removal and clinical response in individual patients.</answer>
<question_number>4</question_number>
<answer>It raises concerns about the safety profile of Kisunla.</answer>
<question_number>5</question_number>
<answer>The potential to stop treatment after clearing amyloid plaques.</answer>
<question_number>6</question_number>
<answer>It might discourage patients from enrolling in other clinical trials.</answer>
<question_number>7</question_number>
<answer>Monthly infusions and the option to discontinue treatment reduce treatment inconvenience.</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>The observation that patients with intermediate tau levels experienced slower decline suggests earlier treatment is more effective.</answer>